Felodipine and Amlodipine Are Equivalent for Antianginal Efficacy
Both felodipine and amlodipine are equally effective dihydropyridine calcium channel blockers for treating chronic stable angina, with no clinically meaningful differences in antianginal efficacy or safety. The choice between them should be based on practical considerations such as cost, availability, and dosing convenience rather than efficacy differences.
Evidence of Equivalence
The most direct evidence comes from a head-to-head randomized, double-blind crossover trial specifically comparing these two agents 1. In 47 patients with documented exercise-induced angina:
- Ischemic episodes per 24 hours: Reduced from 19.9 at baseline to 2.3 with amlodipine and 2.4 with felodipine (p=0.83 between treatments)
- Total ischemia duration: Decreased from 69.8 min/24h to 15.2 min (amlodipine) and 15.5 min (felodipine) (p=0.53 between treatments)
- Anginal attacks: Reduced from 16.4/week to 4.7/week (amlodipine) and 4.3/week (felodipine) (p=0.26 between treatments)
- Nitrate consumption: Decreased from 14.7 capsules/week to 4.0 (amlodipine) and 3.8 (felodipine) (p=0.40 between treatments)
Both drugs were well tolerated with similar adverse event profiles 1.
Guideline Framework
Current guidelines do not distinguish between individual dihydropyridine calcium channel blockers for antianginal efficacy. The 2024 ESC Guidelines classify all calcium channel blockers as first-line antianginal agents alongside beta-blockers 2. The expert consensus emphasizes that felodipine and amlodipine are both dihydropyridines with high selectivity for vascular L-type calcium channels, producing antianginal effects through coronary and systemic vasodilation 3.
Mechanism of Action (Identical Class Effects)
Both agents work identically by:
- Reducing afterload and myocardial oxygen demand
- Producing coronary vasodilation
- Preventing coronary vasospasm (particularly useful in vasospastic angina) 3
Practical Considerations Favoring Amlodipine
While efficacy is equivalent, amlodipine has practical advantages:
- Once-daily dosing with longer half-life (30-50 hours) ensures consistent 24-hour coverage 4
- More extensive clinical trial data in cardiovascular outcomes (CAMELOT, PREVENT trials) 4
- FDA-approved specifically for chronic stable angina, vasospastic angina, and documented CAD 4
- Greater clinical familiarity and formulary availability in most healthcare systems
Clinical Application Algorithm
For patients with chronic stable angina requiring a dihydropyridine CCB:
- Start with amlodipine 5 mg once daily (better studied, more convenient dosing)
- Titrate to 10 mg once daily if symptoms persist after 1-2 weeks
- Consider felodipine 5-10 mg extended-release once daily only if:
- Amlodipine is unavailable or cost-prohibitive
- Patient has documented intolerance to amlodipine specifically (not class effect)
Important Caveats
- Neither drug improves mortality or prevents MI in stable angina patients with preserved left ventricular function 3
- Both are contraindicated in heart failure with reduced ejection fraction (may worsen outcomes) 3
- Avoid in critical peripheral artery disease where acute blood pressure lowering is deleterious 3
- Preferred agents for vasospastic angina where beta-blockers are contraindicated 3
- Can cause reflex tachycardia (less common with long-acting formulations)
- Peripheral edema occurs in ~10% of patients (dose-related, class effect) 4
Combination Therapy
When monotherapy is insufficient, the 2024 ESC Guidelines recommend adding:
- Beta-blocker (if not already prescribed)
- Second-line agents: ivabradine, ranolazine, trimetazidine, long-acting nitrates, or nicorandil 2
Do not combine with non-dihydropyridine CCBs (diltiazem, verapamil) due to excessive negative inotropic effects.
Bottom Line
Choose amlodipine over felodipine for chronic stable angina based on superior convenience (once-daily dosing), more robust clinical trial evidence, and wider availability—not because of any difference in antianginal efficacy, which is equivalent 1.